



- (51) **International Patent Classification:**
C07K 14/82 (2006.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/EP2015/059861
- (22) **International Filing Date:**
5 May 2015 (05.05.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
14167265.9 6 May 2014 (06.05.2014) EP
- (71) **Applicant:** TARGOVAX AS [NO/NO]; Vollsveien 6, N-1366 Lysaker (NO).
- (72) **Inventors:** ERIKSEN, Jon Amund; Targovax AS, Vollsveien 6, N-1366 Lysaker (NO). GAUDERNACK, Gustav; Oslo University Hospital, Radiumhospitalet, Institute for Cancer Research, Dept. of Immunology, Montebello, N-0310 Oslo (NO).
- (74) **Agent:** ARENDS, William Gerrit; Marks & Clerk LLP, 90 Long Acre, London WC2E 9RA (GB).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))



WO 2015/169804 A1

(54) **Title:** PEPTIDE VACCINE COMPRISING MUTANT RAS PEPTIDE AND CHEMOTHERAPEUTIC AGENT

(57) **Abstract:** There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the RAS protein, but has one to three point mutations thereof. The at least one peptide is for use in the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent.